AEDG comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-03-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide emerged from research carried out in Saint Petersburg from the late 1980s onward, where investigators searched for shorter active fragments of a pineal preparation known as epithalamin. The name epitalon was chosen to reflect that parent extract. Early reports described effects on neuroendocrine markers and on the lifespan of laboratory animals. Much of that work appeared in Russian-language journals, with English translations following later, which affects how readily the original protocols can be assessed by outside groups.
Published studies on epitalon are dominated by a small number of research groups, and independent replication in other laboratories remains limited. Proposed mechanisms include activation of telomerase and modulation of melatonin rhythms, but the evidence for either rests mainly on cell cultures and animal models. Whether the peptide produces comparable effects in humans is an open question, and the absence of large controlled trials means the literature is best read as exploratory rather than settled.
Epitalon is a synthetic tetrapeptide whose sequence is alanine-glutamate-aspartate-glycine, written in single-letter code as AEDG. The four residues are joined by three peptide bonds, giving a linear backbone with no branching and no disulfide bridges. Its calculated molecular mass for the free form is approximately 390.3 daltons, a figure that rises when the compound is supplied as an acetate or trifluoroacetate salt. Because the chain is short, the molecule is defined entirely by its residue order rather than by any folded three-dimensional structure.
The compound is described in the literature as a derivative of epithalamin, a preparation obtained from bovine pineal tissue. Work on this peptide family was carried out mainly by a research group in Saint Petersburg beginning in the 1980s, and the substance was later registered for clinical use in Russia under the name Epitalon. Outside that region it is generally treated as a research chemical rather than an approved medicine. Statements about its biological activity rest on a relatively small number of studies, and independent replication remains limited.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C14H22N4O9 | Derived from the four-residue sequence |
| Molar mass | About 390.35 g/mol | Free peptide, counter-ion not included |
| Appearance | White to off-white powder | Lyophilised solid from aqueous solution |
| Water solubility | Freely soluble | Short, polar peptide chain |
| Common synonyms | AEDG; epithalone | Catalogues use the names interchangeably |
Epitalon is a synthetic tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, commonly abbreviated AEDG. Its design traces to epithalamin, a peptide fraction prepared from bovine pineal gland extracts that researchers in Saint Petersburg began investigating in the 1970s. The compound has a molecular formula of C14H22N4O9 and a nominal molecular mass near 390 daltons. It holds no approved drug status in the United States or the European Union, and material sold under this name is generally offered as a research chemical rather than a finished pharmaceutical product.
Proposed mechanisms centre on cell-culture observations rather than a defined receptor interaction. Several reports describe increased expression of the telomerase catalytic subunit after exposure of cultured human cells, and the authors attributed the effect to short peptide fragments entering the nucleus and influencing gene transcription. No receptor for the tetrapeptide has been identified, and the free peptide is expected to be degraded rapidly by plasma peptidases. Whether any measurable fraction reaches intact tissues after administration remains an unresolved question rather than an established finding.
The published literature is dominated by a small number of research groups, much of it in Russian-language journals, and independent replication outside those groups is limited. Studies are typically small, use cultured cells or rodent models, and report endpoints that differ between papers, which makes comparison difficult. Large randomised human trials have not appeared in the indexed literature. Questions about absorption, distribution and clearance are therefore still treated as open in reviews that mention the compound.
Interest in epitalon is usually discussed within the broader field of short peptide bioregulators, a category that includes other synthetic di-, tri-, and tetrapeptides studied by the same research group. These compounds share a common rationale: that small fragments of tissue-derived proteins can retain biological activity and can be produced reproducibly. The category as a whole remains outside mainstream pharmacological consensus, and epitalon specifically has a limited presence in independent, non-Russian research literature, which shapes how its evidence base is described.
Epitalon is a synthetic tetrapeptide with the amino acid sequence alanine-glutamate-aspartate-glycine, abbreviated Ala-Glu-Asp-Gly or AEDG. It was developed by the Russian researcher Vladimir Khavinson and colleagues during work on peptide bioregulators derived from the pineal gland. The compound is short enough to be produced by standard solid-phase peptide synthesis and is typically handled as a lyophilized white powder. Its small size distinguishes it from larger pineal peptides such as epithalamin, a complex extract from which the tetrapeptide was conceptually derived.
Epitalon is a synthetic linear tetrapeptide with the sequence alanine–glutamate–aspartate–glycine, abbreviated AEDG. Its molecular formula is C14H22N4O9 and the calculated mass is approximately 390.35 g/mol. The compound is made by solid-phase peptide synthesis rather than extracted from tissue, although early work described it as a short fragment of a peptide fraction obtained from bovine pineal extract. In the research literature the spelling epitalon and the variant epithalone both appear, while AEDG is the standard code used in peptide nomenclature.
Several names circulate for the same molecule, including epitalon, epithalone, epithalamin tetrapeptide, and the sequence code AEDG. A CAS registry number, 307297-39-8, is commonly cited for it, though catalogue entries should be checked against supplier documentation because mislabelled records occur. In its usual form the peptide carries free amino and carboxyl termini and is neither glycosylated nor lipidated. Researchers distinguish the defined tetrapeptide from epithalamin itself, a crude pineal preparation containing many peptides that is not chemically characterised.
Material supplied for laboratory use is normally a lyophilised white to off-white powder that dissolves readily in water and in isotonic saline. Lyophilised cakes are hygroscopic and should be equilibrated to room temperature before opening to limit condensation on the solid. Solutions are typically prepared at milligram-per-millilitre concentrations and divided into single-use aliquots, because repeated freeze–thaw cycles degrade short peptides. Aqueous solutions are far less stable than the dry powder, and identity is usually verified by mass spectrometry alongside purity estimation from reversed-phase high-performance liquid chromatography.
with a similar structure in 2D. Thus the governing equation is an integro-differential equation similar to Coulomb's and Biot–Savart's law, not convenient for numerical computation. An equivalent weak or variational form of the equation, proved to produce the same velocity solution as the Navier–Stokes equation, is given by,
=== Sevilla === 777 Partners' first investment in soccer was to purchase a minority stake in Spanish La Liga club Sevilla FC in 2018. In 2020, it elevated its share to 7.5%. 777 does not legally own shares in Sevilla as its involvement is as the owner of a group called Sevillistas Unidos S.L.. The latter organization has denounced 777 for listing Sevilla as one of "Our Portfolio Brands" on its website. Sevilla had been identified by 777 Partners as an opportunity for investment due to their focus on buying and selling players under sporting director Monchi. Their investment had been greeted with suspicion due to the club's history of being owned by local dynasties. 777 Partners' investment around Sevilla was allegedly funded in part by a loan from Oleg Boyko, a Russian businessman sanctioned by several countries for reported connections to the Russian state. In 2024, Boyko allegedly demanded 777's shares in Sevilla as collateral for his loan.
Many vulture species are obligately necrophagous including the bearded vulture, black vulture, cinereous vulture, Eurasian griffon, Himalayan vulture, king vulture and turkey vulture. Types of carrion fed upon include dead wildlife, livestock, poultry and companion animals, human remains (sky burial), hunting discards, slaughterhouse offal and roadkill. Typically, muscle tissue is consumed, but bearded vultures feed on bones and bone marrow. In addition to eating carrion, Egyptian vultures feed on small live animals such as turtles, eggs and rotting fruit. Vultures have many adaptations that help them detect, locate and consume carrion. For example, all vultures have keen eyesight, and New World vultures have a highly developed sense of smell. Hooded vultures also have excellent auditory perception, enabling them to hear distant predation-related noises and the distress calls of dying animals. In addition, gliding flight enables vultures to cover long distances to reach carrion, strong beaks allow vultures to cut through thick animal skin, and strong immune defenses protect vultures from pathogens in carrion. Given the inherently unpredictable and ephemeral nature of carrion as a food source, the ability of vultures to survive long periods between meals is also advantageous. Some human activities have had an adverse impact on vultures in Sicily, the Azerbaijan Republic and other countries.
Sources: en.wikipedia.org
Bivalves and the gastropods in the family Juliidae have very similar shells. There are limpet-like forms in several lines of gastropods: "true" limpets, pulmonate siphonariid limpets and several lineages of pulmonate freshwater limpets. Cephalopod (like in octopuses and squid) and vertebrate eyes are both lens-camera eyes with much overall similarity, yet are very unrelated species. A closer examination reveals some differences including embryonic development, extraocular muscles, number of lens parts, and the lack of a retinal blindspot in the cephalopod eye. Swim bladders: buoyant bladders independently evolved in fishes, the tuberculate pelagic octopus, and siphonophores such as the Portuguese man o' war. Bivalves and brachiopods independently evolved paired hinged shells for protection. However, the anatomy of their soft parts is very dissimilar, which is why molluscs and brachiopods are put into different phyla. Jet propulsion in squids and in scallops: these two groups of mollusks have very different ways of squeezing water through their bodies in order to power rapid movement through a fluid. (Dragonfly larvae in the aquatic stage also use an anal jet to propel them, and jellyfish have used jet propulsion for a very long time.) Sea hares (gastropod molluscs) employ a similar means of jet propulsion, but without the sophisticated neurological machinery of cephalopods they navigate somewhat more clumsily. Tunicates (such as salps), and some jellyfish also employ jet propulsion.
== Further reading == Buckley RH (2004). "Molecular defects in human severe combined immunodeficiency and approaches to immune reconstitution". Annu Rev Immunol. 22: 625–55. doi:10.1146/annurev.immunol.22.012703.104614. PMID 15032591. Chinen J, Puck JM (2004). "Successes and risks of gene therapy in primary immunodeficiencies". J Allergy Clin Immunol. 113 (4): 595–603, quiz 604. doi:10.1016/j.jaci.2004.01.765. PMID 15100660. Church AC (2002). "X-linked severe combined immunodeficiency". Hosp Med. 63 (11): 676–80. doi:10.12968/hosp.2002.63.11.1914. PMID 12474613. Gennery AR, Cant AJ (2001). "Diagnosis of severe combined immunodeficiency". J Clin Pathol. 54 (3): 191–5. doi:10.1136/jcp.54.3.191. PMC 1731376. PMID 11253129.
== Mechanism == The hallmark feature of ferroptosis is the iron-dependent accumulation of oxidatively damaged phospholipids, i.e., lipid peroxides. The implication of Fenton chemistry via iron is crucial for the generation of reactive oxygen species and this feature can be exploited by sequestering iron in lysosomes. Reactive oxygen species (ROS) driving ferroptosis originate from three primary sources: the iron-dependent Fenton reaction, mitochondrial oxidative phosphorylation, and the NADPH oxidase (NOX) enzyme family. The NOX family, including NOX1, NOX2 (CYBB), and NOX4, transports electrons across the plasma membrane to produce superoxide and downstream ROS. The pentose phosphate pathway supplies NADPH, which serves as the essential electron donor for GPX4, FSP1/AIFM2, NOX, and POR — meaning that a higher intracellular NADPH ratio correlates with increased resistance to ferroptosis. The incorporation of polyunsaturated fatty acids (PUFAs) into membrane phospholipids is a prerequisite for ferroptosis. Two key enzymes govern this process: acyl-CoA synthetase long-chain family member 4 (ACSL4) activates PUFAs such as arachidonic acid and adrenic acid, and lysophosphatidylcholine acyltransferase 3 (LPCAT3) incorporates these activated PUFAs into the phospholipid bilayer. Monounsaturated fatty acids (MUFAs), including oleic acid and palmitoleic acid, compete with PUFAs for membrane incorporation and suppress ferroptosis due to their lower susceptibility to peroxidation.
Sources: en.wikipedia.org
It is a synthetic tetrapeptide built from alanine, glutamate, aspartate and glycine. The four residues are joined by standard peptide bonds, giving a linear chain rather than a branched structure.
The name derives from epithalamin, a pineal gland extract studied in the former Soviet Union. Researchers proposed that short fragments of that extract carried the biological activity of interest.
No major regulatory agency has approved it as a medicine. It is handled as a research chemical, and products sold under this name are not standardised drugs with defined clinical labelling.
The peptide contains four residues in the order alanine, glutamate, aspartate and glycine, abbreviated AEDG. The chain is linear and held together by three peptide bonds. Its calculated mass for the uncharged free form is about 390.3 daltons.